恩替卡韦治疗慢性乙肝不同厂家间产品经济学比较  

Economics Comparison of Different Manufacturers Products of Entecavir on the Chronic Hepatitis B

作　　者：马莉莉[1] 郭娜[2] 韩晟[2] 管晓东[1] 史录文[1,2] 李文胜[1] MA Li-li;GUO Na;HAN Sheng;GUAN Xiao-dong;SHI Lu-wen;LI Wen-sheng(College of pharmacy Peking University,Beijing 100191, China;International research center of medical management of Peking University,Beijing 100191, China)

机构地区：[1]北京大学药学院,北京100191 [2]北京大学医药管理国际研究中心,北京100191

出　　处：《药品评价》2016年第14期25-30,共6页Drug Evaluation

摘　　要：目的:系统评价恩替卡韦治疗慢性乙肝不同厂家间产品经济学差异。方法:检索2015年5月1日以前恩替卡韦治疗慢性乙肝的随机对照试验,以Jadad7分量表评价纳入的文献质量,采用ADDIS软件进行网状meta分析。结果:检索到包含商品名的恩替卡韦治疗慢性乙肝的文献共9篇,网状Meta结果显示不同商品名治疗慢性乙肝48周HBV DNA阴转率和48周ALT复常率效果差异无统计学意义,最小成本分析结果表明除敏感性分析中按最低价比较时,维力青分散片成本略高于润众分散片之外,按中位价、敏感性分析比较,维力青均为优选方案。结论:维力青相比其他商品名恩替卡韦治疗慢性乙肝经济学方面有优势,但由于纳入研究数量有限,该系统评价有待进一步探讨。Objective: To evaluate the economics of different manufacturers products of entecavir on the chronic hepatitis B. Methods: Literatureretrieval was conducted to search for randomly controlled trials on the economics of entecavir on the chronic hepatitis B before May 1st, 2015. Thequality of included studies was evaluated by Jadad 7 and the ADDIS software was used for network meta-analysis. Results: The network metaanalysisof 9 included RCTs which specified the product names showed that the differences of the rates of HBV DNA zero conversion and ALTnormalization at 48 week were not statistically significant. The minimum cost analysis showed that Weiliqing was a preferred embodiment accordingto the median price and sensitivity analysis in addition to according to the lowest price of sensitivity analysis. Conclusion: It has been demonstratedthat Weiliqing is more economic on the chronic hepatitis B compared with others. High-quality RCTs are required due to the limited number of studiesincluded.

关 键 词：恩替卡韦 慢性乙肝 经济学比较 

分 类 号：R512.62[医药卫生—内科学]